Complarate
Phase 3Biologic
Complarate is one of 34 biologic programs targeting Rheumatoid Arthritis. It is currently in Phase 3.
1
Indications
3
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Orencia
Bristol-Myers SquibbPreclinical
Actemra
RochePreclinical
Rituxan
RochePreclinical
Simponi
Johnson & JohnsonPreclinical
Remicade
OOrganon and Co
Preclinical
Enbrel
IImmunex
Preclinical
Kevzara
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Complarate
AAO GENERIUM
Phase 3
Actos
TakedaPreclinical
Celexa
AbbViePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tocilizumab2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Complarate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- AAO GENERIUM